Add-on Acquisition • Life Science

Roivant Sciences Acquires Silicon Therapeutics

On February 26, 2021, Roivant Sciences acquired life science company Silicon Therapeutics for 450M USD

Acquisition Context

This is Roivant Sciences’ 1st transaction in the Life Science sector.
This is Roivant Sciences’ largest (disclosed) transaction.
This is Roivant Sciences’ 1st transaction in the United States.
This is Roivant Sciences’ 1st transaction in Massachusetts.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	February 26, 2021
Target	Silicon Therapeutics
Sector	Life Science
Buyer(s)	Roivant Sciences
Deal Type	Add-on Acquisition
Deal Value	450M USD

Target Company

Silicon Therapeutics

Boston, Massachusetts, United States

Silicon Therapeutics LLC is a fully integrated drug design and development company focused on small molecule therapeutics. The Silicon Therapeutics proprietary physics-driven drug design platform combines quantum physics, statistical thermodynamics, molecular simulations, a dedicated HPC super-computing cluster, purpose-built software, in-house laboratories and clinical development capabilities. Silicon Therapeutics is based in Boston, Massachusetts.

Explore More Deals

Browse All 215,130 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Roivant Sciences

London, United Kingdom

Category	Company
Founded	2014
Sector	Life Science
Employees	750
Revenue	29M USD (2025)

DESCRIPTION

Roivant Sciences develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies. Roivant Sciences was founded in 2014 and is based in London, United Kingdom.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: Massachusetts	1 of 1
Country: United States	1 of 1
Year: 2021	1 of 1
Size (of disclosed)	1 of 1

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2023-10-23	Telavant New York, New York, United States Telavant is the developer of RVT-3101, a novel TL1A directed antibody. RVT-3101 is a therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Telavant is based in New York, New York.	Sell	$7.1B

DATE

TARGET

DEAL TYPE

VALUE

2023-10-23

Telavant

New York, New York, United States

Telavant is the developer of RVT-3101, a novel TL1A directed antibody. RVT-3101 is a therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Telavant is based in New York, New York.

Sell

$7.1B

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Massachusetts M&A - United States M&A - 2021 M&A